P190030/S004: ActaStim-S
FDA’s recorded scope: Approval for allowance for reconditioning of the ActaStim-S Spine Fusion Stimulator.
Explore this company’s associated devices, FDA decisions and regulatory history.

MedtechLedger currently links 1 FDA record to the applicant name Theragen, Inc.. 1 entry is a PMA supplement. These are records held by this publication, rather than a count of the company’s entire portfolio.
The dated entries run from May 13, 2026 to May 13, 2026. Individual filings may concern different products or changes to an existing application; review the identifier and decision scope on each record.
Product code LOF appears in 1 of the 1 linked filings. The collection spans 1 FDA product code and 1 original PMA application family. These figures describe the filings available here; they do not establish the company’s total device sales or market share.
The largest PMA family in this collection is P190030, with 1 linked entry. Follow the parent application and its dated supplements to distinguish the original device scope from later changes.
Applicant mailing address recorded by FDA: 11220 Assett Loop, Suite 101, Manassas, VA, 20109. Recorded on P190030/S004, decision dated May 13, 2026.
FDA’s recorded scope: Approval for allowance for reconditioning of the ActaStim-S Spine Fusion Stimulator.
Subsidiaries and similarly named applicants can have separate records. The links below preserve the applicant and submission identifiers. Source records are linked on each filing.
| Product / regulatory record | Company | Pathway | Decision date | Source |
|---|---|---|---|---|
ActaStim-SP190030/S004 | Theragen, Inc. | PMA supplement | May 13, 2026 | FDA |
Source updated Nov 9, 2026. Retrieved Nov 21, 2026.